- Nominating Dr. Prabhavathi Fernandes for election to its
Supervisory Board
Amsterdam, the Netherlands and
Holzgerlingen, Germany, May 2, 2016 -- Curetis N.V. (the
"Company" and, together with Curetis GmbH,
"Curetis"), a developer of next-level
molecular diagnostic solutions, today announced the invitation to
its annual general shareholders' meeting ("AGM").
Curetis will hold its AGM on June 16, 2016, at
Steigenberger Hotel, Stationsplein Zuid-West 951, 1117 CE
Schiphol-Oost/Amsterdam, the Netherlands. The meeting is scheduled
to commence at 13.30 hours CEST; registration starts at 12.30 hours
CEST. Also Curetis will be offering electronic pre-voting starting
on May 20, 2016 at 08:00 hours CEST.
A copy of the convening notice for the AGM,
including a description of the formalities to participate in the
AGM, is available at
http://www.curetis.com/en/investors/share-information/annual-general-meeting.html
The most important resolutions in the agenda of
the AGM relate to changes in the Supervisory Board, i.e. the
proposed election of new Supervisory Board member Dr. Prabhavathi
Fernandes (CEO of Cempra Pharmaceuticals, Inc., Chapel Hill, NC,
USA) for a three-year term until 2019, the resignation of Dr. Frank
Mühlenbeck and the re-election of Dr. Holger Reithinger and Dr.
Rudy Dekeyser for another one-year term, respectively.
Also on the agenda is the creation of a new Stock
Option Program for the Company and associated changes to the
Supervisory Board remuneration, making Supervisory Board members
also eligible to such new plan, as well as changes to the
Management Board's Remuneration Policy and Stock Option grants.
Disclaimer
CAUTION - Investigational device.
Limited by Federal (or United States) law to investigational use.
The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on the Curetis Unyvero technology is currently available for
sale in the United States of America or Canada. The analytical and
clinical performance characteristics of any Curetis Unyvero product
which may be sold at some future point in time in the U.S. have not
yet been established.
###
About
Curetis
Founded in 2007, Curetis is a
molecular diagnostics company which focuses on the development and
commercialization of reliable, fast and cost-effective products for
diagnosing severe infectious diseases. The diagnostic solutions of
Curetis enable rapid multi-parameter pathogen and antibiotic
resistance marker detection in only a few hours, a process that
today can take up to days or even weeks with other techniques.
To date, Curetis has raised EUR
44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels
and private equity funds of over EUR 63.5 million. The company is
based in Holzgerlingen near Stuttgart, Germany. Curetis has signed
collaboration agreements with Heraeus Medical and Cempra Inc. as
well as several international distribution agreements covering many
countries across Europe, the Middle East and Asia.
For further
information, please visit www.curetis.com.
Legal
Disclaimer
This document constitutes neither
an offer to buy nor to subscribe securities and neither this
document nor any part of it should form the basis of any investment
decision in Curetis.
The information contained in this
press release has been carefully prepared. However, Curetis bears
and assumes no liability of whatever kind for the correctness and
completeness of the information provided herein. Curetis does not
assume an obligation of whatever kind to update or correct
information contained in this press release whether as a result of
new information, future events or for other reasons.
This press release includes
statements that are, or may be deemed to be, "forward-looking
statements". These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
"believes", "estimates", "anticipates", "expects", "intends",
"may", "will", or "should", and include statements Curetis makes
concerning the intended results of its strategy. By their nature,
forward-looking statements involve risks and uncertainties and
readers are cautioned that any such forward-looking statements are
not guarantees of future performance. Curetis' actual results may
differ materially from those predicted by the forward-looking
statements. Curetis undertakes no obligation to publicly update or
revise forward-looking statements, except as may be required by
law.
According to §§ 190 ff. German Reorganization Act
(UmwG) and by way of enrolment in the commercial register at
district court Stuttgart on March 15, 2016 Curetis plc (AG) changed
its legal form into Curetis Ltd. (GmbH).
Contact details
Curetis
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr@curetis.com or ir@curetis.com
www.curetis.com - www.unyvero.com
International Media &
Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info(@)akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor
Inquiries
The Ruth Group
Lee Roth
lroth@theruthgroup.com
Tel. +1 646 536 7012
20160502_PR_Curetis_EN
Curetis_Logo